Abstract
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders of hematopoietic progenitors manifest by cytopenias, bleeding, infection, and potential for progression to acute myelogenous leukemia. The wide spectrum of clinical manifestations, including variability in illness severity and potential for progression, suggest that myelodysplastic syndromes encompass a multitude of disorders, likely involving numerous pathologic pathways. In fact, it is the effort to understand the underlying biology of these syndromes that has led to recent advances in treatment approaches, including the FDA approval of three new agents (5-azacitidine, decitabine, and lenalidomide) for the treatment of MDS. This review will present data supporting each of the current pathophysiologic pathways implicated in the development and progression of MDS; summarize the emerging clinical paradigms for treating patients with MDS; and offer insights into several novel approaches attempting to improve treatment options for future MDS patients.
Keywords: Myelodysplastic syndrome, pathophysiology, differentiation therapy, epigenetic therapy, bone marrow transplantation, immunomodulation
Current Cancer Drug Targets
Title: Myelodysplastic Syndromes: Review of Pathophysiology and Current Novel Treatment Approaches
Volume: 7 Issue: 6
Author(s): E. D. Warlick and B. D. Smith
Affiliation:
Keywords: Myelodysplastic syndrome, pathophysiology, differentiation therapy, epigenetic therapy, bone marrow transplantation, immunomodulation
Abstract: Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders of hematopoietic progenitors manifest by cytopenias, bleeding, infection, and potential for progression to acute myelogenous leukemia. The wide spectrum of clinical manifestations, including variability in illness severity and potential for progression, suggest that myelodysplastic syndromes encompass a multitude of disorders, likely involving numerous pathologic pathways. In fact, it is the effort to understand the underlying biology of these syndromes that has led to recent advances in treatment approaches, including the FDA approval of three new agents (5-azacitidine, decitabine, and lenalidomide) for the treatment of MDS. This review will present data supporting each of the current pathophysiologic pathways implicated in the development and progression of MDS; summarize the emerging clinical paradigms for treating patients with MDS; and offer insights into several novel approaches attempting to improve treatment options for future MDS patients.
Export Options
About this article
Cite this article as:
Warlick D. E. and Smith D. B., Myelodysplastic Syndromes: Review of Pathophysiology and Current Novel Treatment Approaches, Current Cancer Drug Targets 2007; 7 (6) . https://dx.doi.org/10.2174/156800907781662284
DOI https://dx.doi.org/10.2174/156800907781662284 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Application of NMR Spectroscopy for the Study of Heart Failure
Current Pharmaceutical Design Nesfatin-1 and the Cardiovascular System: Central and Pheripheral Actions and Cardioprotection
Current Drug Targets Cardiovascular Molecular Imaging: New Methodological Strategies
Current Pharmaceutical Design Moving Troponin Testing into the 21st Century: Will Greater Sensitivity Be Met with Greater Sensibility?
Cardiovascular & Hematological Disorders-Drug Targets Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules
Current Medicinal Chemistry Why Not All Hypertensive Patients Are Tachycardic at Rest?
Current Pharmaceutical Design Adverse Drug Reactions in Hospitals: A Narrative Review
Current Drug Safety Genetic and Non-genetic Determinants of Cardiovascular Disease in South Asians
Current Diabetes Reviews The Circulating Endothelial Cell in Cancer: Towards Marker and Target Identification
Current Pharmaceutical Design Neurologic and Cardiovascular Complications in Pediatric Life Threatening Imipramine Poisoning
Current Drug Safety Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment
Current Medicinal Chemistry Downregulation of Hepatic Carbonyl Reductase Type 1 in End-Stage Renal Disease
Drug Metabolism Letters High Glucose-Mediated Imbalance of Nitric Oxide Synthase and Dimethylarginine Dimethylaminohydrolase Expression in Endothelial Cells
Current Neurovascular Research Expression and Function of MicroRNAs in Enamel Development
Current Stem Cell Research & Therapy Optimization of Cardiac Metabolism in Diabetes Mellitus
Current Pharmaceutical Design Side Effects of AAS Abuse: An Overview
Mini-Reviews in Medicinal Chemistry Integrin α4β7 Antagonists: Activities, Mechanisms of Action and Therapeutic Prospects
Current Immunology Reviews (Discontinued) Semicarbazide-Sensitive Amine Oxidase: Current Status and Perspectives
Current Medicinal Chemistry Amyloidosis and Auto-Inflammatory Syndromes
Current Drug Targets - Inflammation & Allergy Opioids, Sleep, and Sleep-Disordered Breathing
Current Pharmaceutical Design